Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Pasello

Showing results (101-110 of 167) with videos related to

Pageof 17
Sort By:
Journal of Clinical Medicine|April 26, 2025
Surgery for Pancoast Tumors in Multimodality Setting: Analysis of Outcomes and Risk FactorsGiorgio Cannone, Eleonora Faccioli, Alberto Busetto, et al.
Thoracic Cancer|November 21, 2020
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease modelAlessandra Buja, Michele Rivera, Anna De Polo, et al.
Oncotarget|November 7, 2015
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical dataGiulia Pasello, Loredana Urso, Manlio Mencoboni, et al.
Frontiers in Oncology|April 8, 2021
P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune MicroenvironmentFederica Pezzuto, Francesca Lunardi, Luca Vedovelli, et al.
Oncology Research and Treatment|May 5, 2017
Clinical Features and Treatment Outcome of Malignant Pleural MesotheliomaManlio Mencoboni, Rosa A Filiberti, Paola Taveggia, et al.
British Journal of Cancer|September 29, 2022
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitorsElisabetta Zulato, Paola Del Bianco, Giorgia Nardo, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2026
Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET studyGiulia Pasello, Giulia Pigato, Cristiana Mulargiu, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 19, 2025
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257)Giulia Pasello, Giulia Pigato, Daniela Scattolin, et al.
Oncotarget|April 22, 2017
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutationsStefano Frega, Martina Lorenzi, Matteo Fassan, et al.
Cancers|November 26, 2022
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic TreatmentsAlessandra Ferro, Matteo Sepulcri, Marco Schiavon, et al.
Pageof 17

Showing results (101-110 of 167) with videos related to

Sort By:
Pageof 17
Journal of Clinical Medicine|April 26, 2025
Surgery for Pancoast Tumors in Multimodality Setting: Analysis of Outcomes and Risk FactorsGiorgio Cannone, Eleonora Faccioli, Alberto Busetto, et al.
Thoracic Cancer|November 21, 2020
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease modelAlessandra Buja, Michele Rivera, Anna De Polo, et al.
Oncotarget|November 7, 2015
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical dataGiulia Pasello, Loredana Urso, Manlio Mencoboni, et al.
Frontiers in Oncology|April 8, 2021
P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune MicroenvironmentFederica Pezzuto, Francesca Lunardi, Luca Vedovelli, et al.
Oncology Research and Treatment|May 5, 2017
Clinical Features and Treatment Outcome of Malignant Pleural MesotheliomaManlio Mencoboni, Rosa A Filiberti, Paola Taveggia, et al.
British Journal of Cancer|September 29, 2022
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitorsElisabetta Zulato, Paola Del Bianco, Giorgia Nardo, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2026
Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET studyGiulia Pasello, Giulia Pigato, Cristiana Mulargiu, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 19, 2025
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257)Giulia Pasello, Giulia Pigato, Daniela Scattolin, et al.
Oncotarget|April 22, 2017
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutationsStefano Frega, Martina Lorenzi, Matteo Fassan, et al.
Cancers|November 26, 2022
The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic TreatmentsAlessandra Ferro, Matteo Sepulcri, Marco Schiavon, et al.
Pageof 17